A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.

PLoS One 2016 7;11(10):e0164499. Epub 2016 Oct 7.

Department of Medicine A, University Hospital Muenster, Muenster, Germany.

Nintedanib (BIBF 1120), a potent multikinase inhibitor of VEGFR-1/-2/-3, FGFR-1/-2/-3 and PDGFR-α/-β, exerts growth inhibitory and pro-apoptotic effects in myeloid leukemic cells, especially when used in combination with cytarabine. This phase I study evaluated nintedanib in combination with low-dose cytarabine (LDAC) in elderly patients with untreated or relapsed/refractory acute myeloid leukemia (AML) ineligible for intensive chemotherapy in a 3+3 design. Nintedanib (dose levels 100, 150, and 200 mg orally twice daily) and LDAC (20 mg subcutaneous injection twice daily for 10 days) were administered in 28-day cycles. Dose-limiting toxicity (DLT) was defined as non-hematological severe adverse reaction CTC grade ≥ 4 with possible or definite relationship to nintedanib. Between April 2012 and October 2013, 13 patients (median age 73 [range: 62-86] years) were enrolled. One patient did not receive study medication and was replaced. Nine (69%) patients had relapsed or refractory disease and 6 (46%) patients had unfavorable cytogenetics. The most frequently reported treatment-related adverse events (AE) were gastrointestinal events. Twelve SAEs irrespective of relatedness were reported. Two SUSARs were observed, one fatal hypercalcemia and one fatal gastrointestinal infection. Two patients (17%) with relapsed AML achieved a complete remission (one CR, one CRi) and bone marrow blast reductions without fulfilling PR criteria were observed in 3 patients (25%). One-year overall survival was 33%. Nintedanib combined with LDAC shows an adequate safety profile and survival data are promising in a difficult-to-treat patient population. Continuation of this trial with a phase II recommended dose of 2 x 200 mg nintedanib in a randomized, placebo-controlled phase II study is planned. The trial is registered to EudraCT as 2011-001086-41.

Trial Registration: ClinicalTrials.gov NCT01488344.

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0164499PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055288PMC
June 2017

Publication Analysis

Top Keywords

low-dose cytarabine
8
elderly patients
8
nintedanib combined
8
myeloid leukemia
8
acute myeloid
8
phase study
8
patients
7
nintedanib
7
study medication
4
disease 46%
4
receive study
4
46% patients
4
refractory disease
4
medication replaced
4
69% patients
4
patients relapsed
4
relapsed refractory
4
replaced 69%
4
cytogenetics frequently
4
twelve saes
4

Similar Publications